Today, Scholar Rock announced that the U.S. Food and Drug Administration (FDA) has delayed approval of the Biologics License Application (BLA) for apitegromab in the treatment of people living with SMA.
We are pleased to share a community letter Biogen, announcing topline results from the Phase 1 study of salanersen (BIIB115) for SMA.
We are pleased to share a community letter from Roche, announcing that the European Commission (EC) has approved a new, room- temperature stable tablet formulation of risdiplam.
We are delighted to invite you to read the latest Spinal cord stimulation: A new perspective for SMA research by Rare Revolution Magazine.